nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Mitoxantrone—multiple sclerosis	0.726	1	CiPCiCtD
Topotecan—ABCG2—Cladribine—multiple sclerosis	0.0387	0.188	CbGbCtD
Topotecan—ABCG2—Mitoxantrone—multiple sclerosis	0.0282	0.137	CbGbCtD
Topotecan—ABCG2—Dexamethasone—multiple sclerosis	0.0146	0.071	CbGbCtD
Topotecan—ABCB1—Methylprednisolone—multiple sclerosis	0.014	0.0677	CbGbCtD
Topotecan—CYP3A4—Fingolimod—multiple sclerosis	0.013	0.0629	CbGbCtD
Topotecan—ABCG2—Methotrexate—multiple sclerosis	0.0118	0.057	CbGbCtD
Topotecan—ABCB1—Mitoxantrone—multiple sclerosis	0.0102	0.0494	CbGbCtD
Topotecan—ABCB1—Betamethasone—multiple sclerosis	0.00907	0.044	CbGbCtD
Topotecan—ABCB1—Prednisolone—multiple sclerosis	0.00895	0.0434	CbGbCtD
Topotecan—ABCB1—Prednisone—multiple sclerosis	0.00845	0.041	CbGbCtD
Topotecan—CYP3A4—Methylprednisolone—multiple sclerosis	0.00836	0.0405	CbGbCtD
Topotecan—CYP3A4—Triamcinolone—multiple sclerosis	0.00634	0.0307	CbGbCtD
Topotecan—CYP3A4—Mitoxantrone—multiple sclerosis	0.0061	0.0296	CbGbCtD
Topotecan—CYP3A4—Betamethasone—multiple sclerosis	0.00544	0.0264	CbGbCtD
Topotecan—CYP3A4—Prednisolone—multiple sclerosis	0.00536	0.026	CbGbCtD
Topotecan—ABCB1—Dexamethasone—multiple sclerosis	0.00528	0.0256	CbGbCtD
Topotecan—CYP3A4—Prednisone—multiple sclerosis	0.00506	0.0246	CbGbCtD
Topotecan—ABCB1—Methotrexate—multiple sclerosis	0.00424	0.0206	CbGbCtD
Topotecan—CYP3A4—Dexamethasone—multiple sclerosis	0.00316	0.0153	CbGbCtD
Topotecan—Irinotecan—BCHE—multiple sclerosis	0.00122	0.709	CrCbGaD
Topotecan—TOP1MT—nervous system—multiple sclerosis	0.000568	0.104	CbGeAlD
Topotecan—TOP1—retina—multiple sclerosis	0.000552	0.101	CbGeAlD
Topotecan—TOP1MT—central nervous system—multiple sclerosis	0.000547	0.0999	CbGeAlD
Topotecan—TOP1MT—cerebellum—multiple sclerosis	0.000534	0.0977	CbGeAlD
Topotecan—Irinotecan—ALB—multiple sclerosis	0.000503	0.291	CrCbGaD
Topotecan—TOP1MT—brain—multiple sclerosis	0.000434	0.0793	CbGeAlD
Topotecan—TOP1—medulla oblongata—multiple sclerosis	0.000399	0.0729	CbGeAlD
Topotecan—TOP1—midbrain—multiple sclerosis	0.000364	0.0666	CbGeAlD
Topotecan—TOP1—spinal cord—multiple sclerosis	0.000355	0.065	CbGeAlD
Topotecan—TOP1—cerebellum—multiple sclerosis	0.000282	0.0515	CbGeAlD
Topotecan—TOP1—brain—multiple sclerosis	0.000229	0.0419	CbGeAlD
Topotecan—ABCG2—medulla oblongata—multiple sclerosis	0.000141	0.0259	CbGeAlD
Topotecan—ABCG2—midbrain—multiple sclerosis	0.000129	0.0236	CbGeAlD
Topotecan—ABCG2—spinal cord—multiple sclerosis	0.000126	0.0231	CbGeAlD
Topotecan—ABCG2—cerebellum—multiple sclerosis	0.0001	0.0183	CbGeAlD
Topotecan—ABCB1—retina—multiple sclerosis	9.65e-05	0.0176	CbGeAlD
Topotecan—ABCG2—brain—multiple sclerosis	8.12e-05	0.0148	CbGeAlD
Topotecan—Angioedema—Triamcinolone—multiple sclerosis	7.74e-05	0.00128	CcSEcCtD
Topotecan—Haemoglobin—Prednisone—multiple sclerosis	7.73e-05	0.00128	CcSEcCtD
Topotecan—Angioedema—Methylprednisolone—multiple sclerosis	7.72e-05	0.00128	CcSEcCtD
Topotecan—Haemorrhage—Prednisone—multiple sclerosis	7.69e-05	0.00128	CcSEcCtD
Topotecan—Malaise—Triamcinolone—multiple sclerosis	7.64e-05	0.00127	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—multiple sclerosis	7.62e-05	0.00127	CcSEcCtD
Topotecan—Malaise—Methylprednisolone—multiple sclerosis	7.62e-05	0.00126	CcSEcCtD
Topotecan—Feeling abnormal—Mitoxantrone—multiple sclerosis	7.55e-05	0.00125	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisolone—multiple sclerosis	7.52e-05	0.00125	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—multiple sclerosis	7.51e-05	0.00125	CcSEcCtD
Topotecan—Dizziness—Azathioprine—multiple sclerosis	7.5e-05	0.00124	CcSEcCtD
Topotecan—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	7.49e-05	0.00124	CcSEcCtD
Topotecan—CYP3A4—nervous system—multiple sclerosis	7.4e-05	0.0135	CbGeAlD
Topotecan—Cough—Triamcinolone—multiple sclerosis	7.39e-05	0.00123	CcSEcCtD
Topotecan—Urticaria—Mitoxantrone—multiple sclerosis	7.28e-05	0.00121	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisolone—multiple sclerosis	7.27e-05	0.00121	CcSEcCtD
Topotecan—Body temperature increased—Mitoxantrone—multiple sclerosis	7.24e-05	0.0012	CcSEcCtD
Topotecan—Abdominal pain—Mitoxantrone—multiple sclerosis	7.24e-05	0.0012	CcSEcCtD
Topotecan—Myalgia—Triamcinolone—multiple sclerosis	7.21e-05	0.0012	CcSEcCtD
Topotecan—Vomiting—Azathioprine—multiple sclerosis	7.21e-05	0.0012	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—multiple sclerosis	7.2e-05	0.00119	CcSEcCtD
Topotecan—Arthralgia—Methylprednisolone—multiple sclerosis	7.2e-05	0.00119	CcSEcCtD
Topotecan—Myalgia—Methylprednisolone—multiple sclerosis	7.2e-05	0.00119	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—multiple sclerosis	7.16e-05	0.00119	CcSEcCtD
Topotecan—Infestation—Methotrexate—multiple sclerosis	7.16e-05	0.00119	CcSEcCtD
Topotecan—Rash—Azathioprine—multiple sclerosis	7.15e-05	0.00119	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	7.15e-05	0.00119	CcSEcCtD
Topotecan—Dermatitis—Azathioprine—multiple sclerosis	7.14e-05	0.00119	CcSEcCtD
Topotecan—Ill-defined disorder—Betamethasone—multiple sclerosis	7.13e-05	0.00118	CcSEcCtD
Topotecan—Ill-defined disorder—Dexamethasone—multiple sclerosis	7.13e-05	0.00118	CcSEcCtD
Topotecan—CYP3A4—central nervous system—multiple sclerosis	7.13e-05	0.013	CbGeAlD
Topotecan—Discomfort—Triamcinolone—multiple sclerosis	7.13e-05	0.00118	CcSEcCtD
Topotecan—Discomfort—Methylprednisolone—multiple sclerosis	7.11e-05	0.00118	CcSEcCtD
Topotecan—Headache—Azathioprine—multiple sclerosis	7.1e-05	0.00118	CcSEcCtD
Topotecan—Angioedema—Betamethasone—multiple sclerosis	7.02e-05	0.00117	CcSEcCtD
Topotecan—Angioedema—Dexamethasone—multiple sclerosis	7.02e-05	0.00117	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—multiple sclerosis	6.98e-05	0.00116	CcSEcCtD
Topotecan—Angiopathy—Prednisone—multiple sclerosis	6.98e-05	0.00116	CcSEcCtD
Topotecan—ABCB1—medulla oblongata—multiple sclerosis	6.97e-05	0.0127	CbGeAlD
Topotecan—Immune system disorder—Prednisone—multiple sclerosis	6.95e-05	0.00115	CcSEcCtD
Topotecan—Malaise—Dexamethasone—multiple sclerosis	6.93e-05	0.00115	CcSEcCtD
Topotecan—Malaise—Betamethasone—multiple sclerosis	6.93e-05	0.00115	CcSEcCtD
Topotecan—Anaphylactic shock—Triamcinolone—multiple sclerosis	6.91e-05	0.00115	CcSEcCtD
Topotecan—Anaphylactic shock—Methylprednisolone—multiple sclerosis	6.9e-05	0.00114	CcSEcCtD
Topotecan—Infection—Triamcinolone—multiple sclerosis	6.87e-05	0.00114	CcSEcCtD
Topotecan—Sweating—Methotrexate—multiple sclerosis	6.86e-05	0.00114	CcSEcCtD
Topotecan—Infection—Methylprednisolone—multiple sclerosis	6.85e-05	0.00114	CcSEcCtD
Topotecan—Alopecia—Prednisone—multiple sclerosis	6.8e-05	0.00113	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—multiple sclerosis	6.77e-05	0.00112	CcSEcCtD
Topotecan—Nervous system disorder—Methylprednisolone—multiple sclerosis	6.77e-05	0.00112	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—multiple sclerosis	6.75e-05	0.00112	CcSEcCtD
Topotecan—Hypersensitivity—Mitoxantrone—multiple sclerosis	6.75e-05	0.00112	CcSEcCtD
Topotecan—Paraesthesia—Prednisolone—multiple sclerosis	6.75e-05	0.00112	CcSEcCtD
Topotecan—Nausea—Azathioprine—multiple sclerosis	6.73e-05	0.00112	CcSEcCtD
Topotecan—Skin disorder—Methylprednisolone—multiple sclerosis	6.7e-05	0.00111	CcSEcCtD
Topotecan—Malnutrition—Prednisone—multiple sclerosis	6.69e-05	0.00111	CcSEcCtD
Topotecan—Hyperhidrosis—Triamcinolone—multiple sclerosis	6.68e-05	0.00111	CcSEcCtD
Topotecan—Hyperhidrosis—Methylprednisolone—multiple sclerosis	6.67e-05	0.00111	CcSEcCtD
Topotecan—Asthenia—Mitoxantrone—multiple sclerosis	6.57e-05	0.00109	CcSEcCtD
Topotecan—Myalgia—Dexamethasone—multiple sclerosis	6.54e-05	0.00109	CcSEcCtD
Topotecan—Myalgia—Betamethasone—multiple sclerosis	6.54e-05	0.00109	CcSEcCtD
Topotecan—Discomfort—Dexamethasone—multiple sclerosis	6.47e-05	0.00107	CcSEcCtD
Topotecan—Discomfort—Betamethasone—multiple sclerosis	6.47e-05	0.00107	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—multiple sclerosis	6.46e-05	0.00107	CcSEcCtD
Topotecan—Pain—Prednisolone—multiple sclerosis	6.43e-05	0.00107	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—multiple sclerosis	6.43e-05	0.00107	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—multiple sclerosis	6.38e-05	0.00106	CcSEcCtD
Topotecan—ABCB1—midbrain—multiple sclerosis	6.37e-05	0.0117	CbGeAlD
Topotecan—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.3e-05	0.00105	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.28e-05	0.00104	CcSEcCtD
Topotecan—Anaphylactic shock—Dexamethasone—multiple sclerosis	6.27e-05	0.00104	CcSEcCtD
Topotecan—Anaphylactic shock—Betamethasone—multiple sclerosis	6.27e-05	0.00104	CcSEcCtD
Topotecan—Diarrhoea—Mitoxantrone—multiple sclerosis	6.27e-05	0.00104	CcSEcCtD
Topotecan—Infection—Dexamethasone—multiple sclerosis	6.23e-05	0.00103	CcSEcCtD
Topotecan—Infection—Betamethasone—multiple sclerosis	6.23e-05	0.00103	CcSEcCtD
Topotecan—ABCB1—spinal cord—multiple sclerosis	6.22e-05	0.0114	CbGeAlD
Topotecan—Ill-defined disorder—Prednisone—multiple sclerosis	6.21e-05	0.00103	CcSEcCtD
Topotecan—Paraesthesia—Triamcinolone—multiple sclerosis	6.21e-05	0.00103	CcSEcCtD
Topotecan—Feeling abnormal—Prednisolone—multiple sclerosis	6.2e-05	0.00103	CcSEcCtD
Topotecan—Paraesthesia—Methylprednisolone—multiple sclerosis	6.19e-05	0.00103	CcSEcCtD
Topotecan—Anaemia—Prednisone—multiple sclerosis	6.19e-05	0.00103	CcSEcCtD
Topotecan—Dyspnoea—Triamcinolone—multiple sclerosis	6.16e-05	0.00102	CcSEcCtD
Topotecan—Nervous system disorder—Betamethasone—multiple sclerosis	6.15e-05	0.00102	CcSEcCtD
Topotecan—Nervous system disorder—Dexamethasone—multiple sclerosis	6.15e-05	0.00102	CcSEcCtD
Topotecan—Thrombocytopenia—Dexamethasone—multiple sclerosis	6.14e-05	0.00102	CcSEcCtD
Topotecan—Thrombocytopenia—Betamethasone—multiple sclerosis	6.14e-05	0.00102	CcSEcCtD
Topotecan—Angioedema—Prednisone—multiple sclerosis	6.12e-05	0.00102	CcSEcCtD
Topotecan—Dyspepsia—Triamcinolone—multiple sclerosis	6.09e-05	0.00101	CcSEcCtD
Topotecan—Dyspepsia—Methylprednisolone—multiple sclerosis	6.07e-05	0.00101	CcSEcCtD
Topotecan—Hyperhidrosis—Dexamethasone—multiple sclerosis	6.06e-05	0.00101	CcSEcCtD
Topotecan—Hyperhidrosis—Betamethasone—multiple sclerosis	6.06e-05	0.00101	CcSEcCtD
Topotecan—Malaise—Prednisone—multiple sclerosis	6.04e-05	0.001	CcSEcCtD
Topotecan—Anorexia—Dexamethasone—multiple sclerosis	5.98e-05	0.000992	CcSEcCtD
Topotecan—Anorexia—Betamethasone—multiple sclerosis	5.98e-05	0.000992	CcSEcCtD
Topotecan—Urticaria—Prednisolone—multiple sclerosis	5.97e-05	0.000991	CcSEcCtD
Topotecan—Fatigue—Triamcinolone—multiple sclerosis	5.96e-05	0.000989	CcSEcCtD
Topotecan—Fatigue—Methylprednisolone—multiple sclerosis	5.95e-05	0.000987	CcSEcCtD
Topotecan—Pain—Triamcinolone—multiple sclerosis	5.91e-05	0.000981	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—multiple sclerosis	5.83e-05	0.000968	CcSEcCtD
Topotecan—Vomiting—Mitoxantrone—multiple sclerosis	5.83e-05	0.000967	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—multiple sclerosis	5.8e-05	0.000963	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—multiple sclerosis	5.79e-05	0.000961	CcSEcCtD
Topotecan—Rash—Mitoxantrone—multiple sclerosis	5.78e-05	0.000959	CcSEcCtD
Topotecan—Dermatitis—Mitoxantrone—multiple sclerosis	5.77e-05	0.000958	CcSEcCtD
Topotecan—Chills—Methotrexate—multiple sclerosis	5.77e-05	0.000957	CcSEcCtD
Topotecan—Headache—Mitoxantrone—multiple sclerosis	5.74e-05	0.000953	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.72e-05	0.000948	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.72e-05	0.000948	CcSEcCtD
Topotecan—Arthralgia—Prednisone—multiple sclerosis	5.7e-05	0.000946	CcSEcCtD
Topotecan—Myalgia—Prednisone—multiple sclerosis	5.7e-05	0.000946	CcSEcCtD
Topotecan—Feeling abnormal—Triamcinolone—multiple sclerosis	5.7e-05	0.000945	CcSEcCtD
Topotecan—Feeling abnormal—Methylprednisolone—multiple sclerosis	5.68e-05	0.000943	CcSEcCtD
Topotecan—Alopecia—Methotrexate—multiple sclerosis	5.68e-05	0.000942	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	5.66e-05	0.000939	CcSEcCtD
Topotecan—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	5.64e-05	0.000936	CcSEcCtD
Topotecan—Paraesthesia—Dexamethasone—multiple sclerosis	5.63e-05	0.000935	CcSEcCtD
Topotecan—Paraesthesia—Betamethasone—multiple sclerosis	5.63e-05	0.000935	CcSEcCtD
Topotecan—Discomfort—Prednisone—multiple sclerosis	5.63e-05	0.000934	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—multiple sclerosis	5.59e-05	0.000928	CcSEcCtD
Topotecan—Hypersensitivity—Prednisolone—multiple sclerosis	5.54e-05	0.000919	CcSEcCtD
Topotecan—Dyspepsia—Betamethasone—multiple sclerosis	5.52e-05	0.000916	CcSEcCtD
Topotecan—Dyspepsia—Dexamethasone—multiple sclerosis	5.52e-05	0.000916	CcSEcCtD
Topotecan—Urticaria—Triamcinolone—multiple sclerosis	5.49e-05	0.000911	CcSEcCtD
Topotecan—Urticaria—Methylprednisolone—multiple sclerosis	5.48e-05	0.000909	CcSEcCtD
Topotecan—Body temperature increased—Triamcinolone—multiple sclerosis	5.47e-05	0.000907	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisone—multiple sclerosis	5.46e-05	0.000907	CcSEcCtD
Topotecan—Abdominal pain—Methylprednisolone—multiple sclerosis	5.45e-05	0.000905	CcSEcCtD
Topotecan—Decreased appetite—Betamethasone—multiple sclerosis	5.45e-05	0.000905	CcSEcCtD
Topotecan—Decreased appetite—Dexamethasone—multiple sclerosis	5.45e-05	0.000905	CcSEcCtD
Topotecan—Nausea—Mitoxantrone—multiple sclerosis	5.44e-05	0.000903	CcSEcCtD
Topotecan—Infection—Prednisone—multiple sclerosis	5.43e-05	0.000901	CcSEcCtD
Topotecan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.42e-05	0.000899	CcSEcCtD
Topotecan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.42e-05	0.000899	CcSEcCtD
Topotecan—Back pain—Methotrexate—multiple sclerosis	5.41e-05	0.000898	CcSEcCtD
Topotecan—Fatigue—Betamethasone—multiple sclerosis	5.41e-05	0.000898	CcSEcCtD
Topotecan—Fatigue—Dexamethasone—multiple sclerosis	5.41e-05	0.000898	CcSEcCtD
Topotecan—Pain—Betamethasone—multiple sclerosis	5.36e-05	0.00089	CcSEcCtD
Topotecan—Pain—Dexamethasone—multiple sclerosis	5.36e-05	0.00089	CcSEcCtD
Topotecan—Nervous system disorder—Prednisone—multiple sclerosis	5.36e-05	0.000889	CcSEcCtD
Topotecan—Skin disorder—Prednisone—multiple sclerosis	5.31e-05	0.000881	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisone—multiple sclerosis	5.28e-05	0.000876	CcSEcCtD
Topotecan—ABCB1—nervous system—multiple sclerosis	5.24e-05	0.00958	CbGeAlD
Topotecan—Anorexia—Prednisone—multiple sclerosis	5.21e-05	0.000864	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—multiple sclerosis	5.19e-05	0.000861	CcSEcCtD
Topotecan—Anaemia—Methotrexate—multiple sclerosis	5.17e-05	0.000858	CcSEcCtD
Topotecan—Feeling abnormal—Dexamethasone—multiple sclerosis	5.17e-05	0.000858	CcSEcCtD
Topotecan—Feeling abnormal—Betamethasone—multiple sclerosis	5.17e-05	0.000858	CcSEcCtD
Topotecan—Gastrointestinal pain—Betamethasone—multiple sclerosis	5.13e-05	0.000851	CcSEcCtD
Topotecan—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5.13e-05	0.000851	CcSEcCtD
Topotecan—Hypersensitivity—Triamcinolone—multiple sclerosis	5.09e-05	0.000845	CcSEcCtD
Topotecan—Hypersensitivity—Methylprednisolone—multiple sclerosis	5.08e-05	0.000843	CcSEcCtD
Topotecan—Malaise—Methotrexate—multiple sclerosis	5.04e-05	0.000837	CcSEcCtD
Topotecan—ABCB1—central nervous system—multiple sclerosis	5.04e-05	0.00922	CbGeAlD
Topotecan—Leukopenia—Methotrexate—multiple sclerosis	5.01e-05	0.000831	CcSEcCtD
Topotecan—Urticaria—Dexamethasone—multiple sclerosis	4.98e-05	0.000827	CcSEcCtD
Topotecan—Urticaria—Betamethasone—multiple sclerosis	4.98e-05	0.000827	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.98e-05	0.000826	CcSEcCtD
Topotecan—Dizziness—Prednisolone—multiple sclerosis	4.97e-05	0.000825	CcSEcCtD
Topotecan—Asthenia—Triamcinolone—multiple sclerosis	4.96e-05	0.000823	CcSEcCtD
Topotecan—Abdominal pain—Betamethasone—multiple sclerosis	4.96e-05	0.000823	CcSEcCtD
Topotecan—Body temperature increased—Dexamethasone—multiple sclerosis	4.96e-05	0.000823	CcSEcCtD
Topotecan—Abdominal pain—Dexamethasone—multiple sclerosis	4.96e-05	0.000823	CcSEcCtD
Topotecan—Body temperature increased—Betamethasone—multiple sclerosis	4.96e-05	0.000823	CcSEcCtD
Topotecan—Asthenia—Methylprednisolone—multiple sclerosis	4.95e-05	0.000821	CcSEcCtD
Topotecan—ABCB1—cerebellum—multiple sclerosis	4.93e-05	0.00901	CbGeAlD
Topotecan—Paraesthesia—Prednisone—multiple sclerosis	4.91e-05	0.000814	CcSEcCtD
Topotecan—Pruritus—Triamcinolone—multiple sclerosis	4.89e-05	0.000812	CcSEcCtD
Topotecan—Cough—Methotrexate—multiple sclerosis	4.88e-05	0.00081	CcSEcCtD
Topotecan—Pruritus—Methylprednisolone—multiple sclerosis	4.88e-05	0.00081	CcSEcCtD
Topotecan—Dyspepsia—Prednisone—multiple sclerosis	4.81e-05	0.000798	CcSEcCtD
Topotecan—Chest pain—Methotrexate—multiple sclerosis	4.76e-05	0.00079	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—multiple sclerosis	4.76e-05	0.00079	CcSEcCtD
Topotecan—Myalgia—Methotrexate—multiple sclerosis	4.76e-05	0.00079	CcSEcCtD
Topotecan—Decreased appetite—Prednisone—multiple sclerosis	4.75e-05	0.000788	CcSEcCtD
Topotecan—Rash—Prednisolone—multiple sclerosis	4.74e-05	0.000787	CcSEcCtD
Topotecan—Dermatitis—Prednisolone—multiple sclerosis	4.74e-05	0.000786	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.73e-05	0.000785	CcSEcCtD
Topotecan—Diarrhoea—Methylprednisolone—multiple sclerosis	4.72e-05	0.000783	CcSEcCtD
Topotecan—Fatigue—Prednisone—multiple sclerosis	4.71e-05	0.000782	CcSEcCtD
Topotecan—Headache—Prednisolone—multiple sclerosis	4.71e-05	0.000782	CcSEcCtD
Topotecan—Discomfort—Methotrexate—multiple sclerosis	4.71e-05	0.000781	CcSEcCtD
Topotecan—Constipation—Prednisone—multiple sclerosis	4.67e-05	0.000775	CcSEcCtD
Topotecan—Dizziness—Triamcinolone—multiple sclerosis	4.57e-05	0.000759	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—multiple sclerosis	4.57e-05	0.000758	CcSEcCtD
Topotecan—Dizziness—Methylprednisolone—multiple sclerosis	4.56e-05	0.000757	CcSEcCtD
Topotecan—Infection—Methotrexate—multiple sclerosis	4.54e-05	0.000753	CcSEcCtD
Topotecan—Feeling abnormal—Prednisone—multiple sclerosis	4.5e-05	0.000747	CcSEcCtD
Topotecan—Asthenia—Dexamethasone—multiple sclerosis	4.5e-05	0.000747	CcSEcCtD
Topotecan—Asthenia—Betamethasone—multiple sclerosis	4.5e-05	0.000747	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—multiple sclerosis	4.48e-05	0.000743	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—multiple sclerosis	4.47e-05	0.000742	CcSEcCtD
Topotecan—Gastrointestinal pain—Prednisone—multiple sclerosis	4.47e-05	0.000741	CcSEcCtD
Topotecan—Nausea—Prednisolone—multiple sclerosis	4.47e-05	0.000741	CcSEcCtD
Topotecan—Pruritus—Dexamethasone—multiple sclerosis	4.44e-05	0.000737	CcSEcCtD
Topotecan—Pruritus—Betamethasone—multiple sclerosis	4.44e-05	0.000737	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—multiple sclerosis	4.43e-05	0.000736	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—multiple sclerosis	4.41e-05	0.000732	CcSEcCtD
Topotecan—Vomiting—Triamcinolone—multiple sclerosis	4.4e-05	0.000729	CcSEcCtD
Topotecan—Vomiting—Methylprednisolone—multiple sclerosis	4.39e-05	0.000728	CcSEcCtD
Topotecan—Rash—Triamcinolone—multiple sclerosis	4.36e-05	0.000723	CcSEcCtD
Topotecan—Dermatitis—Triamcinolone—multiple sclerosis	4.36e-05	0.000723	CcSEcCtD
Topotecan—Anorexia—Methotrexate—multiple sclerosis	4.35e-05	0.000722	CcSEcCtD
Topotecan—Rash—Methylprednisolone—multiple sclerosis	4.35e-05	0.000722	CcSEcCtD
Topotecan—Dermatitis—Methylprednisolone—multiple sclerosis	4.35e-05	0.000721	CcSEcCtD
Topotecan—Urticaria—Prednisone—multiple sclerosis	4.34e-05	0.00072	CcSEcCtD
Topotecan—Headache—Triamcinolone—multiple sclerosis	4.33e-05	0.000719	CcSEcCtD
Topotecan—Headache—Methylprednisolone—multiple sclerosis	4.32e-05	0.000717	CcSEcCtD
Topotecan—Body temperature increased—Prednisone—multiple sclerosis	4.32e-05	0.000717	CcSEcCtD
Topotecan—Abdominal pain—Prednisone—multiple sclerosis	4.32e-05	0.000717	CcSEcCtD
Topotecan—Diarrhoea—Dexamethasone—multiple sclerosis	4.29e-05	0.000712	CcSEcCtD
Topotecan—Diarrhoea—Betamethasone—multiple sclerosis	4.29e-05	0.000712	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.16e-05	0.00069	CcSEcCtD
Topotecan—Dizziness—Dexamethasone—multiple sclerosis	4.15e-05	0.000688	CcSEcCtD
Topotecan—Dizziness—Betamethasone—multiple sclerosis	4.15e-05	0.000688	CcSEcCtD
Topotecan—Nausea—Triamcinolone—multiple sclerosis	4.11e-05	0.000682	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—multiple sclerosis	4.1e-05	0.00068	CcSEcCtD
Topotecan—Nausea—Methylprednisolone—multiple sclerosis	4.1e-05	0.00068	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—multiple sclerosis	4.07e-05	0.000676	CcSEcCtD
Topotecan—Hypersensitivity—Prednisone—multiple sclerosis	4.03e-05	0.000668	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—multiple sclerosis	4.02e-05	0.000667	CcSEcCtD
Topotecan—ABCB1—brain—multiple sclerosis	4.01e-05	0.00732	CbGeAlD
Topotecan—Vomiting—Betamethasone—multiple sclerosis	3.99e-05	0.000662	CcSEcCtD
Topotecan—Vomiting—Dexamethasone—multiple sclerosis	3.99e-05	0.000662	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—multiple sclerosis	3.97e-05	0.000659	CcSEcCtD
Topotecan—Rash—Dexamethasone—multiple sclerosis	3.96e-05	0.000656	CcSEcCtD
Topotecan—Rash—Betamethasone—multiple sclerosis	3.96e-05	0.000656	CcSEcCtD
Topotecan—Dermatitis—Betamethasone—multiple sclerosis	3.95e-05	0.000656	CcSEcCtD
Topotecan—Dermatitis—Dexamethasone—multiple sclerosis	3.95e-05	0.000656	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.94e-05	0.000654	CcSEcCtD
Topotecan—Fatigue—Methotrexate—multiple sclerosis	3.94e-05	0.000653	CcSEcCtD
Topotecan—Headache—Dexamethasone—multiple sclerosis	3.93e-05	0.000652	CcSEcCtD
Topotecan—Headache—Betamethasone—multiple sclerosis	3.93e-05	0.000652	CcSEcCtD
Topotecan—Asthenia—Prednisone—multiple sclerosis	3.92e-05	0.00065	CcSEcCtD
Topotecan—Pain—Methotrexate—multiple sclerosis	3.9e-05	0.000648	CcSEcCtD
Topotecan—Pruritus—Prednisone—multiple sclerosis	3.87e-05	0.000641	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—multiple sclerosis	3.76e-05	0.000624	CcSEcCtD
Topotecan—Diarrhoea—Prednisone—multiple sclerosis	3.74e-05	0.00062	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.73e-05	0.00062	CcSEcCtD
Topotecan—Nausea—Betamethasone—multiple sclerosis	3.73e-05	0.000618	CcSEcCtD
Topotecan—Nausea—Dexamethasone—multiple sclerosis	3.73e-05	0.000618	CcSEcCtD
Topotecan—Urticaria—Methotrexate—multiple sclerosis	3.63e-05	0.000602	CcSEcCtD
Topotecan—Dizziness—Prednisone—multiple sclerosis	3.61e-05	0.0006	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—multiple sclerosis	3.61e-05	0.000599	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—multiple sclerosis	3.61e-05	0.000599	CcSEcCtD
Topotecan—Vomiting—Prednisone—multiple sclerosis	3.47e-05	0.000576	CcSEcCtD
Topotecan—Rash—Prednisone—multiple sclerosis	3.44e-05	0.000572	CcSEcCtD
Topotecan—Dermatitis—Prednisone—multiple sclerosis	3.44e-05	0.000571	CcSEcCtD
Topotecan—Headache—Prednisone—multiple sclerosis	3.42e-05	0.000568	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—multiple sclerosis	3.36e-05	0.000558	CcSEcCtD
Topotecan—Asthenia—Methotrexate—multiple sclerosis	3.28e-05	0.000544	CcSEcCtD
Topotecan—Nausea—Prednisone—multiple sclerosis	3.25e-05	0.000539	CcSEcCtD
Topotecan—Pruritus—Methotrexate—multiple sclerosis	3.23e-05	0.000536	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—multiple sclerosis	3.12e-05	0.000518	CcSEcCtD
Topotecan—Dizziness—Methotrexate—multiple sclerosis	3.02e-05	0.000501	CcSEcCtD
Topotecan—Vomiting—Methotrexate—multiple sclerosis	2.9e-05	0.000482	CcSEcCtD
Topotecan—Rash—Methotrexate—multiple sclerosis	2.88e-05	0.000478	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—multiple sclerosis	2.88e-05	0.000477	CcSEcCtD
Topotecan—Headache—Methotrexate—multiple sclerosis	2.86e-05	0.000475	CcSEcCtD
Topotecan—Nausea—Methotrexate—multiple sclerosis	2.71e-05	0.00045	CcSEcCtD
